Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy

• Status: Unknown status
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the use of Avastin for the management of serosanguinous maculopathy

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Singapore National Eye Centre
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

1. All subfoveal/juxtafoveal CNV and PCV (polypoidal choroidal vasculopathy) who are not eligible for other treatment options (compassionate use)

2. CNV and PCV lesions which have failed PDT, conventional argon laser photocoagulation (salvage use)

3. CNV and PCV lesions treatable with PDT, but cannot afford or refused

Exclusion Criteria:

1. Patients with uncontrolled hypertension (systolic BP greater than 150mmHg or diastolic BP greater than 90mmHg

2. History of thrombolic events such as myocardial infarction or cerebral vascular accident

3. Renal abnormalities (as defined by established history of chronic renal disease or renal failure as well as patients requiring dialysis).

4. Recent (as defined as the past 28 days) or planned (as defined as the next 3 months) surgery.

5. Coagulation abnormalities, including anti-coagulant medication other than aspirin

6. Patients with peptic ulcer disease

7. Pregnant or lactating females